OmniAb, Inc. (OABI)

Market Cap	291.39M +28.8%
Revenue (ttm)	28.94M +8.2%
Net Income	-54.29M
EPS	-0.46
Shares Out	144.97M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,252,511
Open	1.840
Previous Close	1.850
Day's Range	1.801 - 2.020
52-Week Range	1.220 - 2.295
Beta	0.62
Analysts	Buy
Price Target	3.00 (+49.25%)
Earnings Date	May 7, 2026

About OABI

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company’s technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners’ drug development efforts. Its OmniAb platform’s Biological Intelligence powers the immune systems of its proprietary and engineered transgenic anim...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 89
• Stock Exchange: NASDAQ
• Ticker Symbol: OABI
• Website: https://www.omniab.com

Financial Performance

In 2025, OmniAb's revenue was $18.67 million, a decrease of -29.27% compared to the previous year's $26.39 million. Losses were -$64.78 million, 4.43% more than in 2024.

Analyst Summary

According to one analyst, the rating for OABI stock is "Buy" and the 12-month stock price target is $3.0.

Price Target

$3.0

(49.25% upside)

Analyst Consensus: Buy